Profile data is unavailable for this security.
About the company
Guizhou Yibai Pharmaceutical Co Ltd is a China-based company principally engaged in pharmaceutical industry, medical services, and big health industry businesses. The pharmaceutical industry business is mainly engaged in the research and development, production and sales of chemical drugs, traditional Chinese medicines, biological drugs and other drugs. The medical service business is mainly engaged in the operation and management of comprehensive hospitals, tumor specialty hospitals, and tumor radiotherapy centers. The big health industry business is mainly engaged in the development, research, production and sales of big health products featuring Miao medicine. The Company mainly operates its businesses in the domestic market.
- Revenue in CNY (TTM)1.91bn
- Net income in CNY-234.63m
- Incorporated2000
- Employees5.26k
- LocationGuizhou Yibai Pharmaceutical Co LtdNo. 220-1 Baiyun Avenue, Yunyan DistrictGUIYANG 550008ChinaCHN
- Phone+86 85 184705177
- Fax+86 85 184719910
- Websitehttps://www.gzcci.com/
More ▼
Mergers & acquisitions
| Acquired company | 600594:SHH since announced | Transaction value |
|---|---|---|
| Guizhou Yibai Traditional Chinese Medicine Formula Granule Pharmaceutical Co Ltd | -11.87% | 11.15m |
Data delayed at least 15 minutes, as of Feb 13 2026.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hanshang Group Co Ltd | 1.04bn | -7.75m | 2.90bn | 2.24k | -- | 1.74 | -- | 2.80 | -0.0263 | -0.0263 | 3.51 | 5.66 | 0.2992 | 2.45 | 8.58 | 463,254.10 | -0.5073 | 1.38 | -0.911 | 2.59 | 44.80 | 61.66 | -1.70 | 3.79 | 0.3006 | -0.0194 | 0.300 | 17.52 | -15.41 | 0.3108 | -123.83 | -- | 4.52 | -- |
| Novoprotein Scientific Inc | 147.33m | -65.02m | 3.07bn | 566.00 | -- | 1.47 | -- | 20.84 | -0.9301 | -0.9301 | 2.10 | 29.82 | 0.0664 | 0.7531 | 2.20 | 260,302.10 | -2.93 | 4.36 | -3.02 | 4.58 | 62.01 | 74.11 | -44.13 | 26.35 | 24.75 | -- | 0.0227 | 24.96 | -16.73 | 28.80 | -523.69 | -- | 166.98 | -- |
| Shanghai Hile Bio-Technology Co Ltd | 246.35m | 171.34m | 3.13bn | 366.00 | 16.01 | 2.05 | -- | 12.70 | 0.2998 | 0.2998 | 0.3895 | 2.34 | 0.1438 | 0.8346 | 2.49 | 673,097.90 | 11.90 | 4.15 | 14.28 | 5.65 | 75.26 | 52.88 | 82.75 | 25.09 | 6.92 | -- | 0.0106 | 26.17 | 12.59 | -0.5053 | 172.28 | 69.73 | -26.47 | 67.20 |
| GuiZhou YiBai Pharmaceutical Co., Ltd. | 1.91bn | -234.63m | 3.18bn | 5.26k | -- | 1.32 | -- | 1.67 | -0.3003 | -0.3003 | 2.42 | 3.03 | 0.4764 | 1.43 | 9.21 | 362,458.80 | -6.27 | -0.973 | -8.33 | -1.31 | 58.70 | 72.00 | -13.17 | -1.65 | 1.25 | -10.11 | 0.2733 | -- | -22.92 | -8.34 | -406.79 | -- | -13.70 | -- |
| Ginwa Enterprise Group Inc | 550.44m | 78.32m | 3.21bn | 588.00 | 39.82 | 2.02 | -- | 5.83 | 0.2157 | 0.2157 | 1.54 | 4.24 | 0.2885 | 4.56 | 4.97 | 936,120.60 | 4.04 | 0.839 | 4.86 | 0.9762 | 76.30 | 75.14 | 14.00 | 2.83 | 1.84 | -- | 0.0561 | 52.12 | 3.55 | -4.95 | 273.96 | 23.56 | 28.32 | 0.00 |
| Shanghai Shenqi Pharmactcl Inv Mgt CoLtd | 1.88bn | 62.34m | 3.25bn | 1.27k | 53.70 | 1.46 | -- | 1.72 | 0.1186 | 0.1186 | 3.58 | 4.37 | 0.5981 | 4.66 | 5.41 | 1,487,675.00 | 1.85 | -0.6947 | 2.33 | -0.8656 | 44.60 | 53.83 | 3.10 | -1.04 | 2.57 | 31.84 | 0.0745 | -- | -12.48 | 1.23 | 25.24 | -3.20 | -13.91 | -- |
| Lionco Pharmaceutical Group Co Ltd | 430.61m | -118.38m | 3.32bn | 436.00 | -- | 4.52 | -- | 7.72 | -0.1609 | -0.1609 | 0.5928 | 1.02 | 0.3578 | 3.93 | 2.41 | 987,638.40 | -9.84 | -2.45 | -11.09 | -3.13 | 45.89 | 72.39 | -27.49 | -9.67 | 2.80 | -2.73 | 0.2791 | -- | 92.95 | -25.32 | 13.68 | -- | -4.03 | -- |
Data as of Feb 13 2026. Currency figures normalised to Guizhou Yibai Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 1.24m | 0.16% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 806.80k | 0.10% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2025 | 727.70k | 0.09% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2025 | 537.60k | 0.07% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2025 | 229.80k | 0.03% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 148.00k | 0.02% |
| Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2025 | 91.60k | 0.01% |
| SWS MU Fund Management Co., Ltd.as of 30 Jun 2025 | 68.40k | 0.01% |
| China Fund Management Co., Ltd.as of 30 Jun 2025 | 66.80k | 0.01% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 57.30k | 0.01% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
